How's Flo Health doing these days?
In our femtech market deck, you will find everything you need to understand the market
SUMMARY
Flo Health is doing well these days, and the evidence is now strong enough to say it clearly: it is still growing, still monetizing, and increasingly looking like a broader women’s health platform rather than just a period-tracking app.
The first thing that matters is scale. Flo says more than 420 million people have used the app and 77 million use it monthly, which puts it in a different league from most femtech companies.
Growth is no longer explosive, but that is not the right benchmark anymore. Moving from 50 million monthly users in 2023 to 77 million in 2026 shows steady expansion on a very large base, which is harder than growing quickly from a small one.
The subscription story also looks real. Flo Premium has reached 6.6 million sign-ups, and the company’s reported bookings and third-party revenue estimates suggest this is a scaled consumer subscription business, not a large free app with weak monetization.
The product is clearly moving beyond periods. Flo’s perimenopause launch, new Premium perimenopause tools, Mayo Clinic collaboration, and symptom-education framing all point toward a life-stage women’s health strategy.
Perimenopause is probably Flo’s clearest new wedge. The market is large, the knowledge gap is measurable, competitors are moving into the space, and Flo has the consumer funnel to turn education into retention and paid conversion.
The clinical shift is real, but careful. Flo is not trying to become a hospital; it is trying to become the layer that helps users understand symptoms earlier, prepare better for care, and navigate health questions with more confidence.
The AI push looks more structural than cosmetic. Databricks, LLM fine-tuning, AI evaluation frameworks, model infrastructure, and privacy-first clinical language suggest Flo wants AI inside the product core, not just in a chatbot wrapper.
Privacy remains the biggest overhang. Flo has improved its privacy posture with Anonymous Mode, ISO certifications, advisory-board work, and stronger public commitments, but the old legal story still shapes trust in a category where reproductive data is extremely sensitive.
The competitive picture is nuanced. Flo is ahead on scale and monetization, while Clue, Natural Cycles, Stardust, and Midi Health each look stronger in narrower areas such as privacy, regulated contraception, cultural affinity, or clinical care.
Flo’s most non-obvious asset may be research. Large app distribution lets the company produce big women’s health studies, turn findings into product features, and build medical credibility faster than many smaller health startups.
Everything points to the same conclusion: Flo Health is one of the strongest consumer health companies in Europe today, but its next phase depends on whether it can turn scale, data, research, AI, and trust into a durable women’s health platform.
This market map, featured in our femtech market deck, highlights top companies and startups in the femtech market
Is Flo Health still growing these days?
Yes. Flo Health still looks like the category leader, and the recent usage signals look pretty good.
Flo now says more than 420 million people have used the app, with 77 million monthly active users. That is already a different scale from most femtech companies, where “large” often means a few million registered users or a few hundred thousand active patients.
The second signal is that third-party app data still shows current demand. Sensor Tower’s public App Store page estimated 2 million US iOS downloads and $8 million US iOS revenue last month. That is not a perfect worldwide picture, but it tells us Flo is still pulling fresh consumer demand, not just living off old installs.
There is also the user growth over time. Flo was talking about 50 million monthly users in 2023, 67 million in 2024, 73 million in early 2025, and 77 million in 2026. That is not explosive anymore, but it is steady growth on a very large base, which is usually harder than growing from a small one.
Flo Health is not coasting after the unicorn round. It is still adding users, still monetizing the app stores, and still sitting at a scale most women’s health apps do not come close to.
Is Flo Health still making real subscription money now?
Yes. Flo Health is still a serious subscription business, not just a big free app.
Flo’s current Premium page says 6.6 million members have signed up for Flo Premium. Compare that with the “nearly 5 million paid subscribers” figure around the 2024 General Atlantic round, and the direction is pretty obvious: Premium has kept growing after the funding story.
There is the revenue range. The company guided to more than $200 million in gross bookings for 2024. Sifted later reported around $200 million in 2024 revenue and a goal of at least 25% growth in 2025. Business of Apps puts 2025 subscription revenue at $275 million, while Latka estimates $157.6 million. Those estimates do not line up perfectly, but even the lower end is already far beyond the normal consumer health-app range.
Also, Mordor Intelligence notes Flo’s 2024 gross bookings and 5 million paid subscribers imply roughly $40 ARPU, which lines up with the typical annual premium price in the category. So, Flo is actually converting users at a price point that looks sustainable for a mass-market app.
Conclusion? Flo Health’s subscription engine still looks healthy.
As this chart shows, and as featured in our femtech market deck, search interest in femtech has increased significantly
Is Flo Health still just a period app?
No. These days, Flo Health is clearly trying to become a life-stage women’s health app.
The biggest recent move is perimenopause. Flo launched Flo for Perimenopause in July 2025, then added a new Premium perimenopause feature suite in May 2026. That is not a random content tab but a way to keep users as they age out of the classic “period prediction” use case.
There is a second, less obvious signal: the company is using research to justify the expansion. Flo published perimenopause research in February 2025, then worked with Mayo Clinic on a January 2026 global digital study with more than 17,000 women across 158 countries. That gives the product launch a much stronger base than “we noticed menopause is trending.”
There is also something about how Flo is framing the problem. Its perimenopause materials keep coming back to confusion, lack of education, and poor symptom awareness. That is commercially useful because Flo does not need to become a full clinic immediately. It can first own the education and navigation layer.
Flo’s current expansion is less about adding more wellness content and more about extending the customer lifecycle. If Flo can keep a user from menstruation to conception, pregnancy, perimenopause, and menopause, the app becomes much harder to replace.
Is perimenopause becoming Flo Health’s next big wedge now?
Yes. Perimenopause looks like Flo Health’s most important new wedge right now.
The timing is very good. Flo says more than one billion women will have gone through perimenopause and menopause by 2025, and its own survey found that 54% of women did not feel adequately informed about perimenopause symptoms and health effects. That gives Flo a large, under-educated audience with a real reason to seek guidance.
There is Mayo Clinic collaboration. The January 2026 study found the US ranked only sixth in perimenopause knowledge behind the UK, Ireland, Canada, Australia, and the Netherlands. That is a very useful market insight for Flo: even in a large, high-spend healthcare market, the knowledge gap is still wide.
The third signal is the competitive context. Clue launched its own Perimenopause mode for Clue Plus users in 2026, while Midi Health hit a $1 billion valuation in February 2026 after building a clinical menopause and midlife-care platform. So Flo is not alone here. The whole category is moving toward midlife women’s health.
That competition actually makes Flo’s move look better, not worse. The market is validating the category, and Flo has the largest consumer funnel. All things considered, perimenopause is probably the clearest place where Flo can turn existing scale into a bigger health platform.
If you want more recent data on this point, please see our latest femtech market report.
This chart, included in our femtech market deck, shows annual VC investment in femtech startups
Is Flo Health becoming more clinical now?
Yes, but Flo Health is becoming clinical through guidance and symptom intelligence before it becomes clinical through care delivery.
The strongest recent signal is endometriosis. In March 2026, Flo published a peer-reviewed economic evaluation saying its digital Symptom Checker could shorten time to endometriosis diagnosis by more than four years, or more than 50%, if used as intended. That is a very different claim from “track your symptoms.” It starts to connect the app to a measurable healthcare bottleneck.
The second signal is reach. Flo said more than 2.7 million women in the US had used its endometriosis-related Symptom Tracker support. If even a small share of those users move from passive tracking to earlier doctor conversations, Flo becomes part of the diagnostic pathway.
The third signal comes from hiring. Recent Flo job posts mention clinical investigation into the safety and effectiveness of a new medical device, plus roles that sit between research, clinical proof, regulatory requirements, and business metrics. That language usually appears when a company wants to make stronger health claims without getting caught unprepared.
Finally, Flo’s medical leadership is also set up for this direction. Its CMO is described as responsible for clinical product development, medical credibility, clinical safety, medical expert partnerships, scientific validation, and support for new monetization streams. That is exactly the bridge Flo needs if it wants to sell more than content.
Flo Health is moving toward clinical credibility, but carefully. It is not trying to look like a hospital but to become the layer that helps users understand symptoms earlier and arrive at care better prepared.
Is Flo Health’s AI push real, or is it just AI marketing?
It looks real. Flo Health is hiring and rebuilding infrastructure like a company that wants AI inside the core product.
One interesting thing here is the Databricks partnership from June 2025. Databricks said Flo adopted its Data Intelligence Platform to power analytics and AI initiatives, improve cycle prediction accuracy, and speed up AI development. Digital Health also reported that Flo was replacing fragmented data systems and legacy infrastructure, with Databricks fine-tuning LLMs for Ask Flo.
The second signal is the job language. Recent AI/ML platform roles describe a central AI Platform team that lets every product team use AI “safely, efficiently, and at scale.” Other postings mention LLM evaluation frameworks, AI Judges, model deployment pipelines, fine-tuning infrastructure, profile stores, experiment tracking, and monitoring.
Also, we should look at how Flo talks about the product direction. A recent job post described the next generation as “AI-powered, privacy-first, clinically backed.” That phrasing matters because it ties together the three things Flo must solve at once: personalization, trust, and medical credibility.
The interesting bit is that Flo’s AI advantage is not the chatbot itself. A chatbot can be copied. The harder thing to copy is a large, structured, longitudinal women’s health dataset, plus enough infrastructure to personalize guidance safely. That is where Flo may have a real edge if execution is good.
This chart, included in our femtech market deck, shows how Flo Health is capturing share in femtech
Is privacy still a real problem for Flo Health now?
Yes. Privacy is still the biggest cloud over Flo Health, even though the company has clearly spent years trying to repair it.
The recent legal signals are hard to ignore. Flo reached a class-action settlement in July 2025, and the broader settlement process involving Flo, Google, and Flurry has been reported at $59.5 million, with claims still relevant in 2026. Meta, which did not settle, lost a California jury verdict in August 2025 over alleged collection of Flo users’ sensitive health data.
The issue keeps showing up in consumer guidance. After the Meta verdict, Consumer Reports told users to consider deleting their Flo data if they no longer wanted to use the service. That matters because privacy is not only a legal question; it affects consumer trust and brand drag.
Also, the company now pushes Anonymous Mode, says it will never sell user data, has ISO 27001 and ISO 27701 certifications, open-sourced Anonymous Mode, and appointed cybersecurity leaders to a Privacy & Security Advisory Board in January 2025. Those are not cosmetic moves, but they also show how much work the company had to do to rebuild trust.
Flo Health is much more privacy-mature than it used to be, but the old case has not disappeared from the market’s memory. For a company handling reproductive and hormonal data, privacy is still part of the investment case, not a footnote.
If you want more recent data on this point, please see our latest femtech market report.
Is Flo Health ahead of competitors these days?
Yes on scale and monetization. Less obviously yes on trust and clinical depth.
Flo’s scale is hard to match. Tracxn’s 2026 profile ranks Flo first among comparable period-tracking startups, with a much higher score and funding total than smaller tracker competitors. Flo also has tens of millions of MAUs and millions of Premium users, while most direct period-app rivals look much smaller from the outside.
But the competitive map is not only “period app versus period app” anymore. Clue is leaning into science, privacy, and now perimenopause. Stardust has built a stronger cultural and privacy-native feel with younger users. Natural Cycles has a stronger regulated-contraception position. Midi Health is building the clinical-care layer for menopause and midlife women’s health.
That makes Flo’s position more nuanced. It has the consumer app layer, which is incredibly valuable. But if a user wants privacy-first minimal tracking, Clue or smaller privacy-native apps can look cleaner. If she wants clinical menopause care, Midi is closer to the doctor. If she wants FDA-cleared contraception, Natural Cycles has a clearer regulatory story.
So Flo is ahead, but not everywhere. Its job now is to use scale to become trusted and clinically useful before narrower competitors own the most valuable use cases.
This chart, included in our femtech market deck, shows annual funding in femtech startups
Is Flo Health using research as a moat now?
Yes. Flo Health is increasingly using research as one of its main strategic tools.
The Mayo Clinic perimenopause study is the clearest example, but it is not the only one. Flo has also published work on endometriosis diagnosis, perimenopause symptoms, menstrual-cycle changes around menopause, sexual satisfaction and orgasm, and health literacy. In June 2026, it announced a peer-reviewed sexual satisfaction study with nearly 28,000 participants.
That research matters because Flo has something most women’s health startups do not have: huge app distribution. Traditional women’s health studies are often small, slow, and expensive. Flo can reach large self-reported cohorts quickly and then turn the findings into product content, symptom tools, and credibility.
There is a limitation, of course. App-based research can skew toward people who download and engage with Flo, and self-reported data is never the same as clinical records. But that does not kill the strategic point. Flo is building a research flywheel: large user base, large surveys, publishable insights, better product, stronger medical positioning.
As seen above with perimenopause and endometriosis, this is becoming one of Flo’s strongest non-obvious assets. It is not just a content app with doctors reviewing articles. Instead, it is starting to look like a consumer-scale women’s health research machine.
If you want more recent data on this point, please see our latest femtech market report.
Is Flo Health hiring like a company in defensive mode?
No. Flo Health’s recent hiring looks more like a company building its next platform layer.
The most interesting jobs are not generic marketing roles, not at all actually. We found AI/ML platform roles, data infrastructure roles, medical and clinical evidence language, and regulatory-adjacent work. One job described building shared AI infrastructure for every product team. Another referenced clinical investigation into the safety and effectiveness of a new medical device.
There is also a governance signal. Flo added former Match Group CEO Mandy Ginsberg to its board in January 2025. That is useful because Flo’s next phase is partly a consumer-subscription problem: retention, pricing, personalization, trust, and product expansion. A former dating-app CEO is a relevant board addition for that kind of consumer scale.
The headcount is also interesting. Latka’s 2025 profile estimates 685 employees, while other company-intelligence pages point to around 700+ employees. Those numbers are not official audited headcount, but they suggest Flo is already a fairly large organization for a consumer femtech company.
It looks like Flo is putting people behind AI infrastructure, clinical evidence, regulatory readiness, and consumer product expansion.
This chart, included in our femtech market deck, compares the main business model options for menopause telehealth platforms
Is regulation becoming a bigger issue for Flo Health now?
Yes, actually. Regulation is becoming more important for Flo Health because the product is moving closer to medical claims.
The privacy side is already obvious. Flo has the FTC history, the class-action afterlife, Meta’s 2025 verdict, and new consumer-health-data expectations in the background. That means every AI or symptom-guidance feature has to be built with privacy risk in mind from the start.
The clinical side is newer. Once Flo talks about shortening endometriosis diagnosis time, symptom checkers, medical-device investigations, and clinically backed AI, it moves into a stricter zone. It can still be a consumer app, but the claims have to be more carefully evidenced than normal wellness content.
The competitive side also matters. Natural Cycles has a stronger regulated-device identity in contraception, while Midi is operating as a clinical-care provider. Flo is somewhere between those two worlds: more clinical than a tracker, less clinical than a care provider.
If Flo handles it well, the rules could actually favor the company because smaller apps may struggle to fund privacy, evidence, safety, and compliance at the same level.
If you want more recent data on this point, please see our latest femtech market report.
Is Flo Health’s brand getting stronger or more fragile lately?
Both, but the stronger signal right now is that Flo’s brand is becoming more important and more exposed at the same time.
On the positive side, Flo has massive consumer awareness, more than 7 million five-star ratings, 85% of users saying they would recommend the app, and a growing library of medically backed content. Those are strong brand assets in a category where trust is hard to earn.
The second positive signal is institutional credibility. Mayo Clinic, UNFPA, medical experts, scientific advisors, ISO certifications, and General Atlantic all help Flo look more serious than a normal app-store health product. That matters when the company moves into perimenopause and endometriosis, where users are looking for confidence, not just tracking.
But the fragile side is still there. Privacy lawsuits, consumer-advice warnings, and post-Roe sensitivity around reproductive data mean Flo’s brand can be hit quickly if users feel unsafe. In this category, trust compounds slowly and breaks fast.
So the brand is stronger, but also more leveraged. Flo’s name now carries more weight, which is good for conversion and partnerships, but it also means any privacy or AI-safety mistake would be louder than before.
This chart, featured in our femtech market deck, illustrates how revenue is divided among customer segments in the femtech market
How is Flo Health doing these days?
Flo Health is doing well right now, and the evidence is strong enough to say that without hedging.
The company still has category-leading scale, real subscription revenue, fresh product expansion, recent research output, AI infrastructure work, and a clear perimenopause wedge. It is also hiring and organizing like a company trying to become a broader women’s health platform rather than just defend a period tracker.
The risk is whether Flo can keep moving into more sensitive health guidance without reopening the trust problem. Privacy, clinical evidence, and regulatory discipline are now central to the story.
Everything considered together, Flo Health looks like one of the strongest consumer health companies in Europe today.
The company is no longer interesting only because it has a big app but because it may be one of the few femtech companies with enough distribution, revenue, data, and research output to turn women’s health navigation into a real platform.
If you want more recent data on this point, please see our latest femtech market report.
| Question | Answer / check | Signals supporting the answer |
|---|---|---|
| Is Flo still growing these days? | Yes. The app still has category-leader scale and fresh demand. | 420M+ users; 77M MAUs; Sensor Tower recent iOS downloads and revenue; MAU growth from 50M to 77M. |
| Is Flo making real money now? | Yes. Premium looks like a scaled subscription business. | 6.6M Premium members; $200M+ 2024 bookings; third-party 2025 revenue estimates; roughly $40 ARPU. |
| Is Flo still just a period app? | No. Flo is becoming a life-stage women’s health app. | Perimenopause launch; May 2026 Premium features; Mayo study; symptom and education positioning. |
| Is perimenopause the next wedge? | Yes. It is Flo’s strongest recent expansion angle. | 1B+ women life-stage market; 54% uninformed survey; Mayo knowledge-gap study; Clue and Midi moving too. |
| Is Flo becoming more clinical? | Yes, mainly through symptom intelligence and care preparation. | Endometriosis study; 2.7M US users of related support; medical-device hiring language; CMO remit. |
| Is Flo’s AI push real? | Yes. The AI work is infrastructure-heavy, not just chatbot branding. | Databricks partnership; legacy data rebuild; LLM fine-tuning; AI Platform and evaluation hiring. |
| Is privacy still a problem? | Yes. It remains the biggest overhang. | 2025 settlement; 2026 claims process; Meta verdict; Consumer Reports warning; Anonymous Mode and ISO work. |
| Is Flo ahead of competitors? | Yes on scale, less clearly on trust and clinical care. | Tracxn ranking; Flo MAUs and Premium base; Clue privacy/science; Natural Cycles regulation; Midi clinical care. |
| Is research becoming a moat? | Yes. Flo is turning scale into publishable women’s health research. | Mayo collaboration; endometriosis study; perimenopause research; 27,931-person sexual health study. |
| Is hiring defensive? | No. Hiring points to AI, clinical proof, and platform expansion. | AI/ML platform roles; regulatory and medical-device language; Mandy Ginsberg board appointment; 685–700+ employee estimates. |
| Is regulation getting bigger? | Yes. Flo is moving into claims that need stronger evidence. | FTC history; privacy settlements; symptom-checker claims; medical-device hiring; Natural Cycles and Midi comparison. |
| Is Flo’s brand stronger lately? | Yes, but more exposed. | 7M+ five-star ratings; 85% recommendation claim; Mayo/UNFPA/ISO credibility; ongoing privacy scrutiny. |
OUR METHODOLOGY
The main question behind this analysis is easy to answer vaguely and hard to answer well: is Flo Health still just a successful period-tracking app, or is it becoming a stronger women’s health platform?
To avoid relying on intuition, broad market impressions, or vibe-based reasoning, we broke the question into the analytical dimensions that matter most: user growth, paid conversion, product expansion, perimenopause, clinical credibility, AI infrastructure, privacy, competition, research output, hiring, regulation, and brand strength.
For each dimension, we looked at recent signals, prioritized the ones closest to the underlying question, and weighed them together rather than treating any single metric, lawsuit, partnership, launch, or estimate as decisive.
That structured aggregation is what makes the final answer clearer: Flo still has strong scale and monetization, but the more important story is how its product, research, AI, and clinical positioning are moving it toward a broader women’s health platform.
We are not affiliated with Flo Health, its investors, or any company mentioned in this analysis. We do not own shares or hold any financial interest in Flo Health.
This analysis is for informational purposes only and should not be read as investment advice, a recommendation to buy or sell any security, or a valuation opinion.
Key sources used for this analysis include: Flo’s company scale, positioning, recommendation claim, and medical expertise materials, Flo Premium membership information, General Atlantic’s investment announcement, Sensor Tower’s app-store demand signal, Business of Apps’ Flo statistics, Flo’s perimenopause launch announcement, Flo’s May 2026 Premium perimenopause tools announcement, Mayo Clinic’s perimenopause study coverage, Flo and Mayo Clinic’s perimenopause collaboration, Flo’s perimenopause research feature, Flo’s endometriosis symptom-checker study, Business Wire’s endometriosis study coverage, Contemporary OB/GYN’s peer-reviewed endometriosis coverage, Databricks on Flo’s AI and data infrastructure partnership, Digital Health on Flo’s Databricks adoption, Flo’s privacy and security advisory board announcement, Consumer Reports’ privacy guidance after the Meta verdict, Courthouse News on Flo privacy litigation, TechCrunch on the Meta verdict, Clue’s Perimenopause mode, Midi Health’s Series D announcement, Natural Cycles’ contraception positioning, FDA documentation for Natural Cycles, Flo’s sexual satisfaction and orgasm study announcement, and the related Springer peer-reviewed article.
This chart, included in our femtech market deck, shows how cycle tracking app technology has evolved over time
Related blog posts
- How strong is fundraising in the femtech market right now?
- Which companies have raised the most funding in the femtech market?
- Which companies are the most valued in the femtech market?
